Use of in vitro lipid digestion data to explain the in vivo performance of triglyceride-based oral lipid formulations of poorly water-soluble drugs: studies with halofantrine.
about
Fatty acids as therapeutic auxiliaries for oral and parenteral formulationsA simple quantitative approach for the determination of long and medium chain lipids in bio-relevant matrices by high performance liquid chromatography with refractive index detection.Critical concentrations in the dilution of oral self-microemulsifying drug delivery systems.Effect of lipolysis on drug release from self-microemulsifying drug delivery systems (SMEDDS) with different core/shell drug location.Absorption enhancement of adefovir dipivoxil by incorporating MCT and ethyl oleate complex oil phase in emulsion.Effects of PEGylated lipid nanoparticles on the oral absorption of one BCS II drug: a mechanistic investigationThe use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension.Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs.Predictive models for oral drug absorption: from in silico methods to integrated dynamical models.Microemulsions as drug delivery systems to improve the solubility and the bioavailability of poorly water-soluble drugs.Self-nanoemulsifying drug delivery systems: formulation insights, applications and advances.Lipid-based formulations and drug supersaturation: harnessing the unique benefits of the lipid digestion/absorption pathway.Self-assembled structures formed during lipid digestion: characterization and implications for oral lipid-based drug delivery systems.The Precipitation Behavior of Poorly Water-Soluble Drugs with an Emphasis on the Digestion of Lipid Based Formulations.Lipid-associated oral delivery: Mechanisms and analysis of oral absorption enhancement.Review and analysis of FDA approved drugs using lipid-based formulations.The role of lipid-based nano delivery systems on oral bioavailability enhancement of fenofibrate, a BCS II drug: comparison with fast-release formulations.Changes in Bioavailability of Omega-3 (DHA) through Alpha-Tocopheryl Phosphate Mixture (TPM) after Oral Administration in Rats.Influence of fatty acid patterns on the intestinal absorption pathway of quercetin in thoracic lymph duct-cannulated rats.Insights into drug precipitation kinetics during in vitro digestion of a lipid-based drug delivery system using in-line raman spectroscopy and mathematical modeling.Toward the establishment of standardized in vitro tests for lipid-based formulations, part 3: understanding supersaturation versus precipitation potential during the in vitro digestion of type I, II, IIIA, IIIB and IV lipid-based formulations.Solid super saturated self-nanoemulsifying drug delivery system (sat-SNEDDS) as a promising alternative to conventional SNEDDS for improvement rosuvastatin calcium oral bioavailability.Refining in silico simulation to study digestion parameters affecting the bioaccessibility of lipophilic nutrients and micronutrients.In vitro digestion of the self-emulsifying lipid excipient Labrasol(®) by gastrointestinal lipases and influence of its colloidal structure on lipolysis rate.In vitro digestion kinetics of excipients for lipid-based drug delivery and introduction of a relative lipolysis half life.Modulation of lipid digestibility using structured emulsion-based delivery systems: comparison of in vivo and in vitro measurements.Non-linear increases in danazol exposure with dose in older vs. younger beagle dogs: the potential role of differences in bile salt concentration, thermodynamic activity, and formulation digestionA coarse-grained simulation to study the digestion and bioaccessibility of lipophilic nutrients and micronutrients in emulsionIn vitro and in vivo evaluations of the performance of an indirubin derivative, formulated in four different self-emulsifying drug delivery systemsDevelopment of Self-Emulsifying Drug Delivery Systems (SEDDS) for Oral Bioavailability Enhancement of Poorly Soluble DrugsIn vitrolipid digestion models in design of drug delivery systems for enhancing oral bioavailability
P2860
Q26828805-3610CAB6-0F13-4261-8AED-4D35A54E886DQ30543782-DD2FCA1B-BED8-430A-A20A-E17A3452CCD9Q33514056-03FD7107-C83B-40F9-A199-55F811D2E448Q33681221-EBCCC5F8-F448-4162-AFF9-EF6E024F14D4Q33858985-22824284-354E-485F-A786-07D02F668C63Q34610539-CFEBA5D2-14D0-48EC-A481-F20DAEADA417Q36088451-EA4E8630-DEAB-4588-96D6-EBA66EA51E27Q36748145-E0971658-B0DA-478C-A840-04E2CFED5BF0Q36909311-451CE348-E4B5-49ED-B71C-821A9A604CF5Q37702234-8C2651DC-BD04-4BE4-B050-B4E0A243F9D9Q37818332-B10D0881-5C51-4B7F-B1BA-F2D3993C2A39Q38119168-FCA9FE6F-6605-4492-9207-CD10C76BBB11Q38383061-20AB0585-1C2D-4B08-961D-148BBC4FCF4FQ38644728-0EBADF8A-0103-44B0-A87B-FBBB5612E101Q38926514-F99F1C28-1947-4D95-90A3-665BA4E7831BQ39411779-8E557D1A-349C-440D-A668-798FC4AC1DCAQ41889403-65A72BB6-EDFB-40C0-901E-8FB6104FB391Q41997405-F8C79C4E-2EA7-4DF4-A939-6D34A8B5A96EQ43668554-A08D259A-FC9E-41D8-9144-0E6FFAB6BE09Q43852623-5F41EC9B-E34B-4E2C-A025-3C72780A9A00Q44630513-381261B1-BCEB-4E80-A1A8-DBCCEEF93828Q46331136-F8C09095-918B-4B5C-9CBB-6347F69DB09CQ51020970-2C85B239-FF2D-4070-82EF-B3FAF4E5A5F3Q51025911-EAFE987C-D134-4829-80D3-30C6F8908C3FQ51462554-2F9143B9-1D0E-4760-8278-E304C5B97181Q52621803-0AA4EE8D-76E1-4C0F-8820-F4546400F96DQ57152378-C78D7CDE-51D6-46B8-A400-20BCE7DB06B2Q57154636-DA001613-D51A-4EF4-AE82-4407E516B7B4Q58199028-02D9F0EB-6B16-4350-9B9C-FAE1910F48EDQ58199061-FB4C602D-988B-4141-A746-2EC08F209157Q58199115-C1191B3A-E9F9-424F-A781-9044D73AB917
P2860
Use of in vitro lipid digestion data to explain the in vivo performance of triglyceride-based oral lipid formulations of poorly water-soluble drugs: studies with halofantrine.
description
2004 nî lūn-bûn
@nan
2004 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Use of in vitro lipid digestio ...... gs: studies with halofantrine.
@ast
Use of in vitro lipid digestio ...... gs: studies with halofantrine.
@en
type
label
Use of in vitro lipid digestio ...... gs: studies with halofantrine.
@ast
Use of in vitro lipid digestio ...... gs: studies with halofantrine.
@en
prefLabel
Use of in vitro lipid digestio ...... gs: studies with halofantrine.
@ast
Use of in vitro lipid digestio ...... gs: studies with halofantrine.
@en
P2093
P50
P356
P1476
Use of in vitro lipid digestio ...... ugs: studies with halofantrine
@en
P2093
Agnes Taillardat-Bertschinger
Ann Marie Kaukonen
Glenn A Edwards
Jacquelyn M O'Connor
P304
P356
10.1002/JPS.20039
P407
P577
2004-05-01T00:00:00Z